Oppenheimer Reiterates Outperform on Orchard Therapeutics, Maintains $34 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Kevin DeGeeter has reiterated his 'Outperform' rating on Orchard Therapeutics (NASDAQ:ORTX), maintaining a price target of $34.
August 09, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer's reiteration of an 'Outperform' rating and a $34 price target for Orchard Therapeutics could positively influence the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Oppenheimer's reiteration of an 'Outperform' rating and a $34 price target for ORTX could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100